https://www.selleckchem.com/pr....oducts/pilaralisib-x
89). However, the incidence of a breast event was greater for patients with post-NAC PDX engraftment (5-year rate 50.0% vs. 19.6%), but this did not achieve significance ( = 0.11). In treatment-naïve breast cancer receiving standard NAC, PDX engraftment was not prognostic for breast cancer recurrence. Further study is needed to establish whether PDX engraftment in the treatment-resistant setting is prognostic for cancer recurrence. In treatment-naïve breast cancer receiving standard NAC, PDX engraftment was not prognostic for
Like
Comment
Share
